US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

CG Oncology Inc.

39.82

-0.0350-0.09%

Post-market: 39.820.00000.00%19:30 EDT

Volume:560.51K

Turnover:22.29M

Market Cap:3.04B

PE:-22.44

High:40.27

Open:40.19

Low:39.15

Close:39.86

52wk High:40.65

52wk Low:14.80

Shares:76.25M

Float Shares:61.28M

Volume Ratio:0.62

T/O Rate:0.91%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.7747

EPS(LYR):-1.4087

ROE:-16.57%

ROA:-12.85%

PB:4.53

PE(LYR):-28.27

Loading ...

Overview Company News Filings

CG Oncology Announces Promising 24-Month Data for Cretostimogene Monotherapy in High-Risk NMIBC, Prepares for BLA Submission

CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in Bond-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months

THOMSON REUTERS

Director Leonard E. Post Reports Disposal of Common Shares of CG Oncology Inc

CG Oncology Announces Completion of Enrollment in Phase 3 PIVOT-006 Study for Intermediate-Risk Bladder Cancer Treatment

CG Oncology Inc. to Present at Morgan Stanley 23rd Annual Global Healthcare Conference

CG Oncology’s Executive Leadership to Participate in Upcoming Investor Conferences

CG Oncology Initiated at Overweight by Piper Sandler

Piper Sandler Initiates CG Oncology at Overweight With $55 Price Target

MT Newswires Live

CG Oncology Q2 EPS $(0.54) Misses $(0.48) Estimate

CG Oncology Q2 Loss Widens

MT Newswires Live

Earnings Flash (CGON) CG Oncology Posts Q2 Net Loss $0.54 a Share, vs. FactSet Est of $0.46 Loss

MT Newswires Live

CG Oncology Inc - Qtrly Shr Loss $0.54

THOMSON REUTERS

CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates

CG Oncology Inc. Files Initial Statement of Beneficial Ownership for Officer Bob Lapetina

Delaware Superior Court Jury Issues Unanimous Verdict that CG Oncology Owes No Future Royalties or Other Payments to ANI Pharmaceuticals

Leonard E. Post, Director, Reports Disposal of Common Shares of CG Oncology Inc

RBC Cuts Price Target on CG Oncology to $53 From $68, Keeps Outperform, Speculative Risk

MT Newswires Live

CG Oncology Inc. Announces CFO Resignation and Appoints Robert Lapetina as Interim Financial Officer

CG Oncology Is Maintained at Overweight by Morgan Stanley

CG Oncology Inc. Conducted Annual Stockholders Meeting

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CGON/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CGON","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CGON\",,,,,undefined,":{"symbol":"CGON","market":"US","secType":"STK","nameCN":"CG Oncology Inc.","latestPrice":39.82,"timestamp":1759521600000,"preClose":39.855,"halted":0,"volume":560505,"hourTrading":{"tag":"盘后","latestPrice":39.82,"preClose":39.82,"latestTime":"19:30 EDT","volume":12372,"amount":492669.25,"timestamp":1759534205050},"delay":0,"floatShares":61279875,"shares":76247581,"eps":-1.774667,"marketStatus":"Market Closed","change":-0.035,"latestTime":"10-03 16:00:00 EDT","open":40.19,"high":40.265,"low":39.15,"amount":22287870.37455,"amplitude":0.027976,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.774667,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1759737600000},"marketStatusCode":7,"adr":0,"listingDate":1706158800000,"exchange":"NASDAQ","adjPreClose":39.855,"preHourTrading":{"tag":"盘前","latestPrice":40.15,"preClose":39.855,"latestTime":"08:40 EDT","volume":179,"amount":7134.780332,"timestamp":1759495217816},"postHourTrading":{"tag":"盘后","latestPrice":39.82,"preClose":39.82,"latestTime":"19:30 EDT","volume":12372,"amount":492669.25,"timestamp":1759534205050},"volumeRatio":0.6206345586483574,"impliedVol":0.2179,"impliedVolPercentile":0.036},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CGON\",,,,,undefined,":{"symbol":"CGON","floatShares":61279875,"roa":"-12.85%","roe":"-16.57%","lyrEps":-1.408697,"volumeRatio":0.6206345586483574,"shares":76247581,"dividePrice":0,"high":40.265,"amplitude":0.027976,"preClose":39.855,"low":39.15,"week52Low":14.8,"pbRate":"4.53","psRate":"5510.31","week52High":40.65,"institutionHeld":0,"latestPrice":39.82,"eps":-1.774667,"divideRate":0,"volume":560505,"delay":0,"ttmEps":-1.774667,"open":40.19,"prevYearClose":28.68,"prevWeekClose":37.54,"prevMonthClose":40.28,"prevQuarterClose":40.28,"fiveDayClose":37.54,"twentyDayClose":33.07,"sixtyDayClose":27.11},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CGON\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-08","symbol":"CGON","fiscalQuarterEnding":"2025/06","expectedEps":-0.49,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1754625600000,"reportTimeType":"pre","actualEps":-0.54},{"market":"US","date":"2025-05-13","symbol":"CGON","fiscalQuarterEnding":"2025/03","expectedEps":-0.39,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747108800000,"reportTimeType":"pre","actualEps":-0.45},{"market":"US","date":"2025-03-28","symbol":"CGON","fiscalQuarterEnding":"2024/12","expectedEps":-0.41,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743134400000,"reportTimeType":"pre","actualEps":-0.48},{"market":"US","date":"2024-11-12","symbol":"CGON","fiscalQuarterEnding":"2024/09","expectedEps":-0.42,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-0.3}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CGON\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CGON\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.0833,"buy":0.9167,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.9167,"analysts":12,"updateTime":1757390400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CGON\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CGON","date":"2025-10-03","current":-22.438012,"percent":0.693827,"low":-77.942097,"twenty":-44.665332,"median":-31.426132,"eighty":-19.253545,"high":-13.496527,"avg":-34.698188,"sd":15.289123,"marketCap":3038847340},"quantilePoints":[{"date":"2024-01-26","current":-62.124194,"twenty":-62.124194,"median":-62.124194,"eighty":-62.124194,"marketCap":2539823423},{"date":"2024-02-02","current":-61.712969,"twenty":-61.712969,"median":-60.379514,"eighty":-59.355029,"marketCap":2523011292},{"date":"2024-02-09","current":-63.452965,"twenty":-62.124194,"median":-60.590915,"eighty":-59.355029,"marketCap":2594147579},{"date":"2024-02-16","current":-77.177799,"twenty":-70.608092,"median":-61.918582,"eighty":-60.168112,"marketCap":3155259972},{"date":"2024-02-23","current":-75.080046,"twenty":-72.448911,"median":-64.672589,"eighty":-60.20714,"marketCap":3069497532},{"date":"2024-03-01","current":-72.705845,"twenty":-73.870179,"median":-70.608092,"eighty":-60.516111,"marketCap":2972433066},{"date":"2024-03-08","current":-64.818944,"twenty":-72.891228,"median":-69.827533,"eighty":-60.799064,"marketCap":2649992888},{"date":"2024-03-15","current":-60.493345,"twenty":-72.302556,"median":-67.469593,"eighty":-60.20714,"marketCap":2473149409},{"date":"2024-03-22","current":-66.867912,"twenty":-72.162706,"median":-65.355579,"eighty":-60.438055,"marketCap":2733760852},{"date":"2024-03-28","current":-56.207672,"twenty":-71.967566,"median":-64.762028,"eighty":-59.842879,"marketCap":2732086332},{"date":"2024-04-05","current":-51.752186,"twenty":-71.648838,"median":-63.50175,"eighty":-58.14191,"marketCap":2515518513},{"date":"2024-04-12","current":-54.631116,"twenty":-71.284577,"median":-62.382039,"eighty":-56.136384,"marketCap":2655454642},{"date":"2024-04-19","current":-48.420853,"twenty":-71.001624,"median":-61.712969,"eighty":-54.576279,"marketCap":2353592420},{"date":"2024-04-26","current":-49.627262,"twenty":-70.73168,"median":-60.54213,"eighty":-53.208102,"marketCap":2412232322},{"date":"2024-05-03","current":-54.151294,"twenty":-70.286112,"median":-60.183337,"eighty":-53.600185,"marketCap":2632131954},{"date":"2024-05-10","current":-35.176138,"twenty":-69.778748,"median":-59.371617,"eighty":-52.278619,"marketCap":2000537303},{"date":"2024-05-17","current":-36.289307,"twenty":-68.393255,"median":-58.232975,"eighty":-49.860318,"marketCap":2063845445},{"date":"2024-05-24","current":-35.140985,"twenty":-67.52163,"median":-57.330453,"eighty":-49.032283,"marketCap":1998538098},{"date":"2024-05-31","current":-40.179539,"twenty":-67.228921,"median":-56.207672,"eighty":-47.173317,"marketCap":2285090743},{"date":"2024-06-07","current":-40.894311,"twenty":-66.477632,"median":-55.878652,"eighty":-42.192617,"marketCap":2325741235},{"date":"2024-06-14","current":-40.788853,"twenty":-65.885708,"median":-55.522213,"eighty":-41.278647,"marketCap":2319743621},{"date":"2024-06-21","current":-37.625109,"twenty":-65.85969,"median":-54.631116,"eighty":-40.788853,"marketCap":2139815216},{"date":"2024-06-28","current":-35.445642,"twenty":-65.443392,"median":-54.494024,"eighty":-40.683395,"marketCap":2015864537},{"date":"2024-07-05","current":-36.125261,"twenty":-64.796178,"median":-54.151294,"eighty":-39.560851,"marketCap":2054515824},{"date":"2024-07-12","current":-40.378738,"twenty":-64.675841,"median":-53.136814,"eighty":-38.206301,"marketCap":2296419569},{"date":"2024-07-15","current":-41.491907,"twenty":-64.64657,"median":-52.780375,"eighty":-38.236766,"marketCap":2359727711},{"date":"2024-08-02","current":-39.652248,"twenty":-64.6173,"median":-52.752957,"eighty":-38.267232,"marketCap":2255102676},{"date":"2024-08-09","current":-38.949194,"twenty":-63.924553,"median":-51.752186,"eighty":-38.000071,"marketCap":2215118586},{"date":"2024-08-16","current":-40.572681,"twenty":-63.472479,"median":-49.956283,"eighty":-38.105529,"marketCap":2307449488},{"date":"2024-08-23","current":-42.377221,"twenty":-62.965116,"median":-49.723226,"eighty":-38.189896,"marketCap":2410077328},{"date":"2024-08-30","current":-43.2618,"twenty":-62.33047,"median":-48.934948,"eighty":-38.276606,"marketCap":2460385093},{"date":"2024-09-06","current":-44.299706,"twenty":-62.063778,"median":-48.270052,"eighty":-38.375033,"marketCap":2519412871},{"date":"2024-09-13","current":-41.079839,"twenty":-61.869081,"median":-45.980618,"eighty":-38.588613,"marketCap":2336292606},{"date":"2024-09-20","current":-46.127835,"twenty":-61.368222,"median":-44.806865,"eighty":-38.861791,"marketCap":2623382252},{"date":"2024-09-27","current":-43.379744,"twenty":-60.747027,"median":-44.736098,"eighty":-39.046612,"marketCap":2467092795},{"date":"2024-10-04","current":-42.412604,"twenty":-60.551887,"median":-44.517902,"eighty":-39.324835,"marketCap":2412089639},{"date":"2024-10-11","current":-40.667036,"twenty":-60.382766,"median":-44.458898,"eighty":-39.52313,"marketCap":2312815649},{"date":"2024-10-18","current":-43.356155,"twenty":-60.203473,"median":-44.063818,"eighty":-39.574912,"marketCap":2465751255},{"date":"2024-10-25","current":-42.990529,"twenty":-60.177247,"median":-43.698192,"eighty":-39.657154,"marketCap":2444957379},{"date":"2024-10-31","current":-42.837202,"twenty":-60.01213,"median":-43.662809,"eighty":-39.673778,"marketCap":2436237366},{"date":"2024-11-08","current":-46.068863,"twenty":-59.381569,"median":-43.651015,"eighty":-39.804577,"marketCap":2620028401},{"date":"2024-11-15","current":-32.980568,"twenty":-59.208121,"median":-43.63922,"eighty":-39.654701,"marketCap":2400853462},{"date":"2024-11-22","current":-30.044833,"twenty":-58.542987,"median":-43.538968,"eighty":-38.997903,"marketCap":2187143689},{"date":"2024-11-29","current":-32.283796,"twenty":-58.232975,"median":-43.444613,"eighty":-38.328163,"marketCap":2350131206},{"date":"2024-12-06","current":-31.17825,"twenty":-58.005312,"median":-43.379744,"eighty":-38.000071,"marketCap":2269651893},{"date":"2024-12-13","current":-26.821099,"twenty":-57.745125,"median":-43.279491,"eighty":-37.543086,"marketCap":1952468717},{"date":"2024-12-20","current":-26.031423,"twenty":-56.915781,"median":-43.120267,"eighty":-36.394765,"marketCap":1894983493},{"date":"2024-12-27","current":-27.044066,"twenty":-56.349294,"median":-43.061296,"eighty":-36.125261,"marketCap":1968699839},{"date":"2025-01-03","current":-26.914002,"twenty":-56.207672,"median":-43.037707,"eighty":-35.33784,"marketCap":1959231684},{"date":"2025-01-10","current":-28.298257,"twenty":-56.136384,"median":-42.978735,"eighty":-34.953504,"marketCap":2059999900},{"date":"2025-01-17","current":-27.034776,"twenty":-55.969133,"median":-42.872585,"eighty":-33.374909,"marketCap":1968023542},{"date":"2025-01-24","current":-32.158189,"twenty":-55.840266,"median":-42.689773,"eighty":-32.852839,"marketCap":2340987506},{"date":"2025-01-31","current":-31.530712,"twenty":-55.653821,"median":-42.565931,"eighty":-32.283796,"marketCap":2295309701},{"date":"2025-02-07","current":-31.405216,"twenty":-55.437216,"median":-42.394913,"eighty":-32.036945,"marketCap":2286174140},{"date":"2025-02-14","current":-29.805151,"twenty":-55.004006,"median":-42.206678,"eighty":-31.677123,"marketCap":2169695737},{"date":"2025-02-21","current":-29.512328,"twenty":-54.631116,"median":-41.999801,"eighty":-31.530712,"marketCap":2148379428},{"date":"2025-02-28","current":-25.768383,"twenty":-54.494024,"median":-41.775708,"eighty":-31.373843,"marketCap":1875835192},{"date":"2025-03-07","current":-28.226,"twenty":-54.39406,"median":-41.609082,"eighty":-31.094637,"marketCap":2054739928},{"date":"2025-03-14","current":-27.138374,"twenty":-54.151294,"median":-41.292708,"eighty":-30.560445,"marketCap":1975565066},{"date":"2025-03-21","current":-29.020804,"twenty":-53.671473,"median":-41.068045,"eighty":-30.21301,"marketCap":2112598481},{"date":"2025-03-28","current":-28.173711,"twenty":-53.493253,"median":-40.922206,"eighty":-29.826066,"marketCap":2050933444},{"date":"2025-04-04","current":-16.223536,"twenty":-52.780375,"median":-40.788853,"eighty":-29.478125,"marketCap":1428303862},{"date":"2025-04-11","current":-15.26259,"twenty":-52.725539,"median":-40.592885,"eighty":-29.073094,"marketCap":1343703153},{"date":"2025-04-17","current":-17.504797,"twenty":-52.648767,"median":-40.36956,"eighty":-28.807616,"marketCap":1541104808},{"date":"2025-04-25","current":-18.630229,"twenty":-51.927664,"median":-39.710836,"eighty":-28.715432,"marketCap":1640186719},{"date":"2025-05-02","current":-24.014988,"twenty":-51.631545,"median":-39.587801,"eighty":-28.276198,"marketCap":2114255557},{"date":"2025-05-09","current":-20.891121,"twenty":-50.318205,"median":-39.192738,"eighty":-28.046644,"marketCap":1839233409},{"date":"2025-05-16","current":-18.305859,"twenty":-49.931606,"median":-38.624431,"eighty":-27.822323,"marketCap":1932311557},{"date":"2025-05-23","current":-18.60193,"twenty":-49.805481,"median":-38.19927,"eighty":-27.481395,"marketCap":1963563934},{"date":"2025-05-30","current":-18.941329,"twenty":-49.745161,"median":-38.000071,"eighty":-27.137812,"marketCap":1999389828},{"date":"2025-06-06","current":-19.230179,"twenty":-49.665648,"median":-37.795014,"eighty":-26.986466,"marketCap":2029879952},{"date":"2025-06-13","current":-19.136302,"twenty":-49.503879,"median":-37.543086,"eighty":-26.644583,"marketCap":2019970662},{"date":"2025-06-20","current":-18.977435,"twenty":-49.032283,"median":-37.168124,"eighty":-26.449487,"marketCap":2003201094},{"date":"2025-06-27","current":-18.825789,"twenty":-48.437304,"median":-36.365471,"eighty":-26.243173,"marketCap":1987193779},{"date":"2025-07-03","current":-19.425152,"twenty":-48.360533,"median":-36.207284,"eighty":-25.994262,"marketCap":2050460785},{"date":"2025-07-11","current":-19.576798,"twenty":-47.916755,"median":-36.101826,"eighty":-24.54782,"marketCap":2066468099},{"date":"2025-07-18","current":-20.551667,"twenty":-47.047797,"median":-35.158562,"eighty":-23.322415,"marketCap":2169372265},{"date":"2025-07-25","current":-18.876337,"twenty":-46.758067,"median":-34.836328,"eighty":-20.953178,"marketCap":1992529551},{"date":"2025-08-01","current":-19.273506,"twenty":-46.459723,"median":-33.67043,"eighty":-19.630235,"marketCap":2034453470},{"date":"2025-08-08","current":-17.583734,"twenty":-46.116041,"median":-33.231407,"eighty":-19.436706,"marketCap":1856086249},{"date":"2025-08-15","current":-15.454183,"twenty":-46.05471,"median":-32.738157,"eighty":-19.425152,"marketCap":1979387202},{"date":"2025-08-22","current":-15.466089,"twenty":-45.994601,"median":-32.283796,"eighty":-19.321744,"marketCap":1980912154},{"date":"2025-08-29","current":-15.90364,"twenty":-45.910989,"median":-32.179105,"eighty":-19.234852,"marketCap":2036954126},{"date":"2025-09-05","current":-18.418814,"twenty":-45.632471,"median":-32.073773,"eighty":-19.17963,"marketCap":2359100156},{"date":"2025-09-12","current":-19.740397,"twenty":-45.219668,"median":-31.708497,"eighty":-19.194072,"marketCap":2528369785},{"date":"2025-09-19","current":-23.109837,"twenty":-44.877631,"median":-31.635292,"eighty":-19.201294,"marketCap":2959931094},{"date":"2025-09-26","current":-21.716818,"twenty":-44.736098,"median":-31.530712,"eighty":-19.230179,"marketCap":2781511754},{"date":"2025-10-03","current":-23.725981,"twenty":-44.665332,"median":-31.426132,"eighty":-19.253545,"marketCap":3038847340}],"updateTime":1759699360889},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CGON\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2565529335","title":"CG Oncology Announces Promising 24-Month Data for Cretostimogene Monotherapy in High-Risk NMIBC, Prepares for BLA Submission","url":"https://stock-news.laohu8.com/highlight/detail?id=2565529335","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565529335?lang=en_us&edition=fundamental","pubTime":"2025-09-05 19:00","pubTimestamp":1757070042,"startTime":"0","endTime":"0","summary":"CG Oncology, Inc. has announced updated data from its BOND-003 Cohort C study, revealing that 12 additional patients with high-risk non-muscle invasive bladder cancer  achieved complete response at 24 months. The study highlights a 24-month complete response rate of 41.8% for cretostimogene monotherapy in patients unresponsive to Bacillus Calmette Guerin  treatment. The safety profile of cretostimogene remained consistent, with no grade 3 or greater treatment-related adverse events or deaths reported. These findings will be presented at the New England Section of the American Urological Association's 94th annual meeting in Boston, Massachusetts. CG Oncology is preparing to initiate a Biologics License Application  submission for cretostimogene in the fourth quarter of the year, aiming to offer a new therapeutic option for patients with HR NMIBC.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250905:nNDL9LZtbS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGON","LU2095319765.USD","IE00BKPKM429.USD","IE00BGHQF748.EUR","NDAQ","IE00B64PRP62.GBP","LU2210149790.SGD","LU0314104364.USD","BK4139","IE00B3QW5Z07.USD","BK4112","LU2210150020.SGD","BK4585","BK4588"],"gpt_icon":0},{"id":"2565552380","title":"CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in Bond-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2565552380","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565552380?lang=en_us&edition=fundamental","pubTime":"2025-09-05 19:00","pubTimestamp":1757070001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250905:nTUAB8MGM9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CGON"],"gpt_icon":0},{"id":"2565882855","title":"Director Leonard E. Post Reports Disposal of Common Shares of CG Oncology Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2565882855","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2565882855?lang=en_us&edition=fundamental","pubTime":"2025-09-05 04:46","pubTimestamp":1757018816,"startTime":"0","endTime":"0","summary":"Leonard E. Post, a director at CG Oncology Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CG Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 04, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250904:nNDLbwYxsQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CGON"],"gpt_icon":0},{"id":"2564398732","title":"CG Oncology Announces Completion of Enrollment in Phase 3 PIVOT-006 Study for Intermediate-Risk Bladder Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2564398732","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564398732?lang=en_us&edition=fundamental","pubTime":"2025-09-03 20:02","pubTimestamp":1756900920,"startTime":"0","endTime":"0","summary":"CG Oncology Inc. has announced the completion of enrollment for its Phase 3, randomized, open-label clinical trial, PIVOT-006. The study is designed to compare the efficacy of adjuvant intravesical cretostimogene grenadenorepvec against standard surveillance following bladder tumor removal in patients with intermediate-risk non-muscle invasive bladder cancer . The trial, which is one of the largest randomized studies in this patient population, has enlisted over 360 participants across more than 90 sites. The high rate of enrollment reflects the significant unmet need for new treatment options in this area. The results of the study have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CG Oncology Inc. published th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250903:nNDLbmF02T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","CGON","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","BK4112","LU0314104364.USD","LU2095319765.USD","NDAQ","LU2210149790.SGD","BK4139","IE00B64PRP62.GBP","LU2210150020.SGD","IE00BKPKM429.USD","BK4588"],"gpt_icon":0},{"id":"2563793040","title":"CG Oncology Inc. to Present at Morgan Stanley 23rd Annual Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2563793040","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563793040?lang=en_us&edition=fundamental","pubTime":"2025-08-29 20:00","pubTimestamp":1756468815,"startTime":"0","endTime":"0","summary":"CG Oncology Inc. announced that its executive leadership will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference, scheduled for September 9, 2025, at 7:45am ET in New York, NY. The company, which focuses on developing bladder-sparing therapeutics for bladder cancer, will be presenting at the event. A live audio webcast of the presentation will be available on the company's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CG Oncology Inc. published the original content used to generate this news brief via GlobeNewswire  on August 29, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250829:nNDLbszDJT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ1G4Q59.USD","LU0106831901.USD","LU1363072403.SGD","LU2023251221.USD","LU2028103732.USD","BK4139","LU0225283273.USD","NDAQ","LU1732799900.SGD","LU0795875169.SGD","LU1668664300.SGD","LU1720051017.SGD","LU2111349929.HKD","LU0098860793.USD","LU2210149790.SGD","CGON","LU0234570918.USD","LU1720051108.HKD","BK4112","LU1732800096.USD","LU1548497426.USD","LU1244550494.USD","BK4581","IE00B64PRP62.GBP","LU2095319765.USD","LU0267386448.USD","IE00BKVL7J92.USD","BK4534","LU2210150020.SGD","LU0158827948.USD","LU1244550577.SGD","LU2357305700.SGD","LU1074936037.SGD","LU1244550221.USD","LU2347655156.SGD","LU2271345857.HKD","BK4585","LU0320765646.SGD","BK4504","LU1989772840.SGD","LU2089284900.SGD","LU0314104364.USD","IE00BKPKM429.USD","BK4127","LU0971096721.USD","LU1989772923.USD","LU0882574139.USD","LU0912757837.SGD","LU0158827781.USD","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2563702833","title":"CG Oncology’s Executive Leadership to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2563702833","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563702833?lang=en_us&edition=fundamental","pubTime":"2025-08-29 20:00","pubTimestamp":1756468800,"startTime":"0","endTime":"0","summary":"IRVINE, Calif., Aug.  29, 2025  (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bla","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/29/3141447/0/en/CG-Oncology-s-Executive-Leadership-to-Participate-in-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","BK4516","BK4534","LU2028103732.USD","LU2347655156.SGD","LU2089284900.SGD","LU2271345857.HKD","LU2089283258.USD","LU0098860793.USD","BK4139","LU0795875169.SGD","LU0106831901.USD","LU1720051108.HKD","LU0158827781.USD","BK4127","LU0314104364.USD","BK4504","LU1074936037.SGD","LU0158827948.USD","LU1244550494.USD","IE00B3QW5Z07.USD","LU2133065610.SGD","LU1548497426.USD","LU0006306889.USD","IE00BKVL7J92.USD","CG","LU0106261372.USD","LU0971096721.USD","IE00B64PRP62.GBP","IE00BZ1G4Q59.USD","LU1244550221.USD","LU1720051017.SGD","LU0912757837.SGD","LU2357305700.SGD","LU2023251221.USD","BK4585","LU1244550577.SGD","BK4581","LU1668664300.SGD","LU1732799900.SGD","LU1989772923.USD","LU1732800096.USD","IE00BGHQF748.EUR","LU2111349929.HKD","LU0320765646.SGD","LU0225283273.USD","LU0795875086.SGD","CGON","BK4588","LU0267386448.USD"],"gpt_icon":0},{"id":"2560960581","title":"CG Oncology Initiated at Overweight by Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2560960581","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560960581?lang=en_us&edition=fundamental","pubTime":"2025-08-19 20:12","pubTimestamp":1755605520,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CGON/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 19, 2025 08:12 ET (12:12 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CG","CGON"],"gpt_icon":0},{"id":"2560160199","title":"Piper Sandler Initiates CG Oncology at Overweight With $55 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2560160199","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560160199?lang=en_us&edition=fundamental","pubTime":"2025-08-19 18:29","pubTimestamp":1755599370,"startTime":"0","endTime":"0","summary":"CG Oncology (CGON) has an average rating of buy and mean price target of $59.90, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks a","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CG","CGON"],"gpt_icon":0},{"id":"2557452087","title":"CG Oncology Q2 EPS $(0.54) Misses $(0.48) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2557452087","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557452087?lang=en_us&edition=fundamental","pubTime":"2025-08-08 21:43","pubTimestamp":1754660582,"startTime":"0","endTime":"0","summary":"CG Oncology (NASDAQ:CGON) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.48) by 12.27 percent. This is a 92.86 percent decrease over losses of $(0.28) per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/46998369/cg-oncology-q2-eps-0-54-misses-0-48-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CGON","CG"],"gpt_icon":0},{"id":"2557524896","title":"CG Oncology Q2 Loss Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2557524896","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557524896?lang=en_us&edition=fundamental","pubTime":"2025-08-08 20:15","pubTimestamp":1754655316,"startTime":"0","endTime":"0","summary":"CG Oncology  reported a Q2 loss Friday of $0.54 per diluted share, compared with a loss of $0.28 a year earlier.Analysts polled by FactSet expected a loss of $0.46.The company did not report any revenue for the quarter ended June 30. It reported license and collaboration revenue of $111,000 a year earlier.Analysts polled by FactSet expected $100,000.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4135","IE00B3QW5Z07.USD","CG","BK4139","IE00BGHQF748.EUR","CGON","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2557521471","title":"Earnings Flash (CGON) CG Oncology Posts Q2 Net Loss $0.54 a Share, vs. FactSet Est of $0.46 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2557521471","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557521471?lang=en_us&edition=fundamental","pubTime":"2025-08-08 20:04","pubTimestamp":1754654674,"startTime":"0","endTime":"0","summary":"Earnings Flash (CGON) CG Oncology Posts Q2 Net Loss $0.54 a Share, vs. FactSet Est of $0.46 Loss","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CG","CGON"],"gpt_icon":0},{"id":"2557521417","title":"CG Oncology Inc - Qtrly Shr Loss $0.54","url":"https://stock-news.laohu8.com/highlight/detail?id=2557521417","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557521417?lang=en_us&edition=fundamental","pubTime":"2025-08-08 20:00","pubTimestamp":1754654401,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250808:nTUA6HPLT2:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CGON","BK4139"],"gpt_icon":0},{"id":"2557752521","title":"CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2557752521","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557752521?lang=en_us&edition=fundamental","pubTime":"2025-08-08 20:00","pubTimestamp":1754654400,"startTime":"0","endTime":"0","summary":"- Announced best-in-disease durability data in BOND-003 Cohort C and promising early signal in Cohort P for cretostimogene grenadenorepvec at the American Urological Association Annual Meeting - - Ini","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/08/3130103/0/en/CG-Oncology-Reports-Second-Quarter-2025-Financial-Results-and-Provides-Business-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BK4135","BK4161","BK4203","CR","HR","CG","IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4139","BK4225","CGON"],"gpt_icon":0},{"id":"2557307370","title":"CG Oncology Inc. Files Initial Statement of Beneficial Ownership for Officer Bob Lapetina","url":"https://stock-news.laohu8.com/highlight/detail?id=2557307370","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557307370?lang=en_us&edition=fundamental","pubTime":"2025-08-07 04:15","pubTimestamp":1754511353,"startTime":"0","endTime":"0","summary":"CG Oncology Inc. has filed an initial statement of beneficial ownership, with Bob Lapetina identified as the beneficial owner in the role of an officer. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CG Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 06, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nNDL1L1rx6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CGON"],"gpt_icon":0},{"id":"2555175069","title":"Delaware Superior Court Jury Issues Unanimous Verdict that CG Oncology Owes No Future Royalties or Other Payments to ANI Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2555175069","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555175069?lang=en_us&edition=fundamental","pubTime":"2025-07-30 04:05","pubTimestamp":1753819500,"startTime":"0","endTime":"0","summary":"IRVINE, Calif., July  29, 2025  (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bla","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/29/3123605/0/en/Delaware-Superior-Court-Jury-Issues-Unanimous-Verdict-that-CG-Oncology-Owes-No-Future-Royalties-or-Other-Payments-to-ANI-Pharmaceuticals.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","LU1559883803.SGD","ANIP","IE00B64PRP62.GBP","CGON","IE00BGHQF748.EUR","SPN","BK4007","BK4139","CG","LU0566484027.USD","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2552490873","title":"Leonard E. Post, Director, Reports Disposal of Common Shares of CG Oncology Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2552490873","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552490873?lang=en_us&edition=fundamental","pubTime":"2025-07-19 04:30","pubTimestamp":1752870636,"startTime":"0","endTime":"0","summary":"Leonard E. Post, a Director and beneficial owner, reported a disposal of common shares of CG Oncology Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CG Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 18, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250718:nNDLb5PKfP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CGON"],"gpt_icon":0},{"id":"2551214065","title":"RBC Cuts Price Target on CG Oncology to $53 From $68, Keeps Outperform, Speculative Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2551214065","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551214065?lang=en_us&edition=fundamental","pubTime":"2025-07-16 19:41","pubTimestamp":1752666085,"startTime":"0","endTime":"0","summary":"CG Oncology (CGON) has an average rating of buy and mean price target of $54, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CGON","CG"],"gpt_icon":0},{"id":"2550296910","title":"CG Oncology Inc. Announces CFO Resignation and Appoints Robert Lapetina as Interim Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2550296910","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550296910?lang=en_us&edition=fundamental","pubTime":"2025-07-12 04:16","pubTimestamp":1752264964,"startTime":"0","endTime":"0","summary":"CG Oncology Inc. announced that Chief Financial Officer Corleen Roche has resigned, effective August 5, 2025. Robert Lapetina, who has been with the company since May 2024 as Vice President of Financial Planning & Analysis, will step in as interim principal financial and accounting officer starting the same day. Lapetina will serve in this interim role until a permanent replacement is found.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CG Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 11, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250711:nNDL6ptH9b:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CGON"],"gpt_icon":0},{"id":"2544996193","title":"CG Oncology Is Maintained at Overweight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2544996193","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544996193?lang=en_us&edition=fundamental","pubTime":"2025-06-17 23:13","pubTimestamp":1750173180,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CGON/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 17, 2025 11:13 ET (15:13 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CG","CGON"],"gpt_icon":0},{"id":"2541898292","title":"CG Oncology Inc. Conducted Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2541898292","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541898292?lang=en_us&edition=fundamental","pubTime":"2025-06-07 04:16","pubTimestamp":1749240978,"startTime":"0","endTime":"0","summary":"CG Oncology Inc. held its 2025 Annual Meeting of Stockholders on June 5, 2025. Stockholders voted on the election of three Class I directors: Arthur Kuan, James J. Mulé, and Leonard Post. All three were elected. Additionally, stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CG Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 06, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250606:nNDL12ht1f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CGON"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":61,"code":"91000000","status":"200"}]}}